GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PROKIDNEY CORP

Financial Performance:

• No specific revenue, profit margins, or cash flow guidance provided beyond current status.
• Cash position reported at $142 million as of September, sufficient to fund operations through mid-2027.
• Company is pre-revenue, late-stage clinical development with no commercial sales yet.

Guidance and Future Outlook:

• Enrollment expected to conclude in Q1 2027.
• Accelerated approval data readout targeted for Q2 2027.
• Manufacturing capacity plan: Launch with 350 patients/year, expanding to 850 by Year 2 and 1,350 by Year 3, with a long-term goal of 3,000 patients/year within 3–4 years.
• Strategic focus remains exclusively on the U.S. market for the immediate future; international expansion via strategic partnerships is a future consideration.

Business Segments and Product Lines:

• Primary asset: Roparinsel (autologous cell therapy), designed to stabilize kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes.
• Treatment mechanism: Cells harvested via kidney biopsy, expanded ex vivo, and re-injected into kidneys to induce cytoprotective effects.
• Phase 3 trial design: Randomized, sham-controlled, two-arm, blinded study with patients having GFR 20–35, diabetes, and CKD.
• Primary endpoint: Accelerated approval based on eGFR slope difference (50% improvement expected: 1.5 vs. 3.0 mL/min/year).
• Confirmatory endpoint: Time to composite events (dialysis, transplant, 40% eGFR loss, or death).
• Commercial launch strategy: "Renal partnership network" targeting 8–10 high-volume centers with certified interventional radiologists initially, expanding as manufacturing scales.

Market and Competitive Landscape:

• Total Addressable Market (TAM): Approximately 1.1 million patients with Stage 3b/4 CKD and type 2 diabetes in the U.S.
• Target patient profile: High-risk patients progressing despite standard of care (RAS inhibitors, SGLT2 inhibitors, and GLP-1 agonists).
• Differentiation: First autologous cell therapy in nephrology; no viral vectors or genetic modification required, allowing for outpatient administration without immunosuppression.
• Regulatory environment: Aligned with 2019 Executive Order and recent HHS Kidney Care Plan prioritizing innovation to prevent kidney failure; enjoys bipartisan political support.
• Pricing strategy: Targeting "cell therapy-like" pricing tiers; details not finalized but anticipated to be in the established range for rare disease/cell therapies.

Risks and Challenges:

• Manufacturing scaling: Requires successful tech transfer and capacity expansion phases in 2026–2027.
• Patient identification and pathway: Reliance on a new referral network between nephrologists and interventional radiologists; requires establishing efficient "patient journeys."
• Competitive landscape: Potential entry of other small molecule or cell therapies, though current pipeline for late-stage CKD is limited.
• Reimbursement: Uncertainty regarding payer acceptance and pricing levels for novel cell therapies despite high unmet need.

Management Commentary and Tone:

• Tone: Highly confident, emphasizing the "single purpose" of preventing dialysis and the robustness of the Phase 3 design.
• Management expressed strong belief in the clinical data, citing a 78% improvement in kidney function decline slope from Phase 2 data.
• Leadership highlighted the strategic advantage of not requiring viral vectors or immunosuppression, simplifying patient logistics compared to other cell therapies.

Analyst Questions and Answers:

• Mechanism of Action: Confirmed cytoprotective effects, reduced oxidative damage, and improved vascular integrity via secreted factors; cells observed in grafts around the subcapsular region.
• Interaction with Standard of Care: Trial protocol requires patients to be on RAS inhibitors/SGLT2 inhibitors or have failed them; randomization stratified by SGLT2 use to ensure balance.
• Commercial Viability: Addressed historical struggles of cell therapies by emphasizing the large, existing U.S. patient population and the non-invasive (outpatient) administration profile.
• Intellectual Property: Disclosed strong IP positioning and significant "know-how" regarding manufacturing processes, creating a competitive moat.
• Global Expansion: CEO reiterated sole focus on the U.S. due to market size and unmet need; open to partners for non-U.S. territories post-launch.

Other Key Points:

• Company has 250 employees, primarily based in North and South Carolina, with manufacturing operations in Winston-Salem, NC.
• Phase 3 trial uses a rigorous "true sham" control group where patients undergo biopsy and procedure simulations but receive no active cell therapy.
• The company is leveraging recent FDA discussions to ensure the label will include use alongside standard of care (SGLT2, GLP-1).
• No new product launches mentioned; all focus is on the single asset roparinsel.